ALS Ltd (ASX: ALQ) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ALS Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $6.98 billion
P/E Ratio 540.75
Dividend Yield 2.74%
Shares Outstanding 484.57 million
Earnings per share 0.027
Dividend per share 0.39
Year To Date Return 16.78%
Earnings Yield 0.18%
Franking 20
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • ALS Ltd (ASX: ALQ)
    Latest News

    Share Market News

    Here are the top 10 ASX 200 shares today

    Thank the RBA for today's happy showing.

    Read more »

    A team of people giving the thumbs up sign representing APA and Wesfarmers doing a deal to study green hydrogen transport using an APA gas pipeline
    Broker Notes

    4 ASX 200 stocks just upgraded by top brokers

    Which four ASX 200 companies have caught the experts' attention?

    Read more »

    A young woman sits at her desk in deep contemplation with her hand to her chin while seriously considering information she is reading on her laptop
    Industrials Shares

    This ASX 200 stock is down 14% since April, and a director just bought over $500k worth

    An inside buyer has purchased a bigger stake in this professional services company.

    Read more »

    A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
    Dividend Investing

    2 ASX 300 shares trading ex-dividend this week

    You'll have to be quick if you want the latest dividends from these ASX shares.

    Read more »

    A worried man holds his head and look at his computer.
    Share Fallers

    Why ALS, IDP Education, Predictive Discovery, and Telix shares are falling

    These ASX shares are missing out on the good times on Monday.

    Read more »

    A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
    Share Market News

    5 things to watch on the ASX 200 on Monday

    It looks set to be a great day for investors on Monday!

    Read more »

    Two brokers pointing and analysing a share price.
    Broker Notes

    4 ASX 200 shares just upgraded by brokers, one with 18% upside

    Analysts have run the ruler over these stocks and come away more bullish.

    Read more »

    ASX shares Business man marking buy on board and underlining it
    Broker Notes

    Leading brokers name 3 ASX shares to buy today

    Analysts believe that now could be the time to add these shares to your portfolio...

    Read more »

    Smiling man with phone in wheelchair watching stocks and trends on computer
    Share Market News

    5 things to watch on the ASX 200 on Monday

    It looks set to be a good start to the week for ASX 200 shares.

    Read more »

    Family smile and laugh as they look at a laptop.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Promising inflation data likely helped bolster the ASX 200 on Wednesday.

    Read more »

    A happy group of workers around a table raise their arms in the air as though celebrating a work achievement. One woman is on her feet with her arm raised in the air in a fist-pumping action.
    Share Gainers

    Why ALS, Centaurus Metals, Pilbara Minerals, and Westgold shares are rising today

    These ASX shares are rising more than most on Wednesday.

    Read more »

    excited person holding australian cash in both hands
    Dividend Investing

    3 ASX 200 shares trading ex-dividend next week  

    If you want to receive the payouts, you’ll need to own these ASX 200 shares at least one day before…

    Read more »

    Frequently Asked Questions

    Yes, ALS Ltd historically pays two partially or fully franked dividends a year.

    ALS Ltd generally pays its shareholder dividends in July and December

    ALS Ltd listed on the ASX on 18 July 1952.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    12 Jun 2024 $0.1960 20.00% Final 02 Jul 2024
    23 Nov 2023 $0.1960 20.00% Interim 14 Dec 2023
    09 Jun 2023 $0.1940 10.00% Final 06 Jul 2023
    24 Nov 2022 $0.2030 0.00% Interim 16 Dec 2022
    06 Jun 2022 $0.1700 30.00% Final 04 Jul 2022
    02 Dec 2021 $0.1580 30.00% Interim 17 Dec 2021
    07 Jun 2021 $0.1460 70.00% Final 05 Jul 2021
    26 Nov 2020 $0.0850 100.00% Interim 16 Dec 2020
    05 Jun 2020 $0.0610 70.00% Final 06 Jul 2020
    27 Nov 2019 $0.1150 30.00% Interim 16 Dec 2019
    03 Jun 2019 $0.1150 35.04% Final 01 Jul 2019
    29 Nov 2018 $0.1100 20.00% Interim 18 Dec 2018
    06 Jun 2018 $0.0900 40.00% Final 02 Jul 2018
    29 Nov 2017 $0.0800 40.00% Interim 18 Dec 2017
    07 Jun 2017 $0.0000 0.00% Final 03 Jul 2017
    05 Dec 2016 $0.0550 60.00% Interim 21 Dec 2016
    08 Jun 2016 $0.0600 40.00% Final 01 Jul 2016
    03 Dec 2015 $0.0750 25.07% Interim 18 Dec 2015
    11 Jun 2014 $0.2000 50.00% Final 02 Jul 2014
    07 Jun 2013 $0.2700 50.00% Final 02 Jul 2013
    05 Jun 2009 $0.4250 0.00% Final 01 Jul 2009
    01 Dec 2008 $0.4250 58.82% Interim 17 Dec 2008
    06 Jun 2008 $0.5100 58.82% Final 01 Jul 2008
    30 Nov 2007 $0.2975 58.82% Interim 17 Dec 2007
    06 Jun 2007 $0.3570 58.82% Final 02 Jul 2007
    29 Nov 2006 $0.2380 58.82% Interim 15 Dec 2006
    05 Jun 2006 $0.2900 100.00% Final 03 Jul 2006
    25 Nov 2005 $0.2100 100.00% Interim 20 Dec 2005
    04 Jun 2004 $0.1900 100.00% Final 01 Jul 2004
    28 Nov 2003 $0.1400 100.00% Interim 19 Dec 2003

    ALQ ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About ALS Ltd

    ALS Ltd (ASX: ALQ) is one of the world's largest laboratory testing, inspection, certification, and verification businesses. It operates from around 350 sites across 65 countries.

    Listed on the ASX in 1952, ALS operates three divisions: commodities, life sciences, and industrial. ALS's commodities segment traditionally generates the majority of the company's underlying earnings. It provides geochemistry, metallurgy, inspection, and mine site services for the mining industry globally.

    The company also provides environmental, pharmaceutical, and food and beverage testing and certification. ALS Ltd has a multi-billion dollar market capitalisation and is part of the ASX 100.

    ALQ Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    09 Oct 2024 $14.45 $0.05 0.35% 659,860 $14.52 $14.66 $14.44
    08 Oct 2024 $14.40 $-0.16 -1.10% 726,465 $14.46 $14.52 $14.25
    07 Oct 2024 $14.56 $0.02 0.14% 490,176 $14.54 $14.75 $14.47
    04 Oct 2024 $14.54 $0.26 1.82% 1,183,932 $14.21 $14.57 $14.03
    03 Oct 2024 $14.28 $0.10 0.71% 903,650 $14.27 $14.40 $14.11
    02 Oct 2024 $14.18 $-0.08 -0.56% 1,011,383 $14.28 $14.32 $14.16
    01 Oct 2024 $14.26 $-0.16 -1.11% 885,343 $14.43 $14.55 $14.25
    30 Sep 2024 $14.42 $0.09 0.63% 1,627,817 $14.29 $14.59 $14.23
    27 Sep 2024 $14.33 $0.23 1.63% 1,353,259 $14.21 $14.37 $14.12
    26 Sep 2024 $14.10 $0.37 2.69% 1,701,461 $13.79 $14.11 $13.77
    25 Sep 2024 $13.73 $0.08 0.59% 1,367,659 $13.79 $13.82 $13.65
    24 Sep 2024 $13.65 $-0.02 -0.15% 2,177,497 $13.76 $13.85 $13.48
    23 Sep 2024 $13.67 $-0.19 -1.37% 2,224,258 $13.70 $13.89 $13.66
    20 Sep 2024 $13.86 $0.19 1.39% 4,817,716 $13.80 $13.98 $13.45
    19 Sep 2024 $13.67 $-1.28 -8.56% 6,657,527 $13.85 $13.85 $13.09
    18 Sep 2024 $14.95 $0.13 0.88% 1,987,284 $14.74 $14.96 $14.67
    17 Sep 2024 $14.82 $-0.09 -0.60% 1,286,719 $14.97 $14.99 $14.79
    16 Sep 2024 $14.91 $-0.14 -0.93% 1,029,591 $15.10 $15.12 $14.82
    13 Sep 2024 $15.05 $0.40 2.73% 1,449,079 $14.80 $15.10 $14.75
    12 Sep 2024 $14.65 $-0.29 -1.94% 2,476,216 $15.04 $15.05 $14.59
    11 Sep 2024 $14.94 $-0.02 -0.13% 1,345,525 $14.96 $14.98 $14.69
    10 Sep 2024 $14.96 $0.15 1.01% 1,285,093 $14.87 $14.98 $14.71

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    08 Aug 2024 Nigel Garrard Buy 2,250 $33,412
    On-market trade.
    31 Jul 2024 Malcom Deane Issued 163,082 $2,304,360
    Issue of securities. 398,893 Rights
    01 Jul 2024 Malcom Deane Expiry 424 $5,952
    As advised by the company. 257,297 - Performance Rights
    424 Performance Rights forfeited
    01 Jul 2024 Malcom Deane Exercise 21,486 $301,663
    Conversion of securities. 2,35,811 - Performance Rights & Service Rights
    01 Jul 2024 Malcom Deane Issued 18,088 $253,955
    Issue of securities. 257,721 - Performance Rights
    As per announcement on 04/07/2024.
    01 Jul 2024 Malcom Deane Buy 21,486 $301,663
    Conversion of securities.
    28 Jun 2024 Nigel Garrard Buy 2,750 $39,595
    On-market trade.
    23 May 2024 Nigel Garrard Buy 4,550 $63,572
    On-market trade.
    19 Dec 2023 Nigel Garrard Buy 3,150 $40,477
    On-market trade.
    23 Nov 2023 Nigel Garrard Buy 3,250 $40,007
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Nigel David Garrard Non-Executive Deputy ChairmanNon-Executive Director Jun 2023
    Mr Garrard is an experienced executive with a track record across the fast-moving consumer goods and industrial/manufacturing sectors. He has over 20 years' experience as an ASX-listed CEO across three companies. In 2019, he retired as Managing Director and CEO of Orora Limited. He led the demerger of Orora Limited from Amcor, and the subsequent listing of Orora Limited on ASX in 2013. He was President of the Amcor Australasia and Packaging Distribution business group, Managing Director of Coca-Cola Amatil's Food and Services Division, and Managing Director of SPC Ardmona. Nigel brings international experience across listed, not-for-profit, government and private entities. He is currently the Chairman of Ansell Limited, a non-executive director of CSR Ltd, Chairman of Flinders Port Holdings Pty Ltd, and Chairman of the McMahon Services advisory board. He is the Chair of the People Committee.
    Dr John Francis Mulcahy Non-Executive Director Feb 2012
    Dr Mulcahy is Chairman of Orix Australia Corporation Limited, an unlisted public company (appointed March 2016), and Deputy Chairman of GWA Group Limited (appointed November 2010). He is also a current Non-Executive Director of Zurich Australia Insurance subsidiaries. John was previously a director and Chairman of both Mirvac Group Limited (November 2009 - December 2022) and Coffey International Limited (September 2009 - January 2016). He is a former Guardian of the Future Fund of Australia and former Managing Director and Chief Executive Officer of Suncorp-Metway Limited. Prior to Suncorp, John held executive roles at the Commonwealth Bank and Lend Lease Corporation. He is a member of the Sustainability and Innovation Committee.
    Ms Tonianne Dwyer Non-Executive Director Jul 2016
    Ms Dwyer has experience as a company director and executive working in finance, corporate strategy and mergers and acquisitions across a variety of sectors and international markets. She is an internationally experienced independent company director, having had a 25-year executive career in investment banking during which she held roles with Hambros Bank Limited and Societe General in the UK and Europe. Tonianne currently holds a non-executive directorship role with Incitec Pivot Limited (appointed May 2022). She is Deputy Chancellor of the Senate of the University of Queensland and is on the Board of the Sir John Monash Foundation. Her previous roles included non-executive director positions with OZ Minerals Limited, DEXUS Property Group and DEXUS Wholesale Property Fund. She is a member of the People Committee and a member of the Risk Committee.
    Ms Leslie A Desjardins Non-Executive Director Nov 2019
    Ms Desjardins has a background as a CFO and senior financial and governance professional in a range of multinational and global businesses. She has commercial and financial governance expertise with multinational public companies in North America, Canada and Australia, each with global operations. Her areas of expertise include CFO level executive and financial strategic leadership, M&A, corporate finance and treasury, governance, financial and tax compliance, and enterprise risk management. Leslie is currently a Director, Audit Committee Chair, Human Resource Committee member with Ansell Limited. Previously, she served as a Board Director and Audit Committee member with AptarGroup. During her executive career, Leslie served as Executive VP and CFO at Amcor Limited, a global leader in packaging of food, beverage, pharmaceutical and tobacco products. Prior to Amcor Ltd, Leslie served in financial and corporate strategic positions with General Motors Corporation, including Chief Financial Officer GM Holden Australia, Controller GM North America, Executive Director Manufacturing Finance and Director GM North America Strategy and Planning. She is the Chair of the Risk Committee, a member of the Sustainability and Innovation Committee.
    Dr Siddhartha Kadia Non-Executive Director Jan 2019
    Dr Kadia was formerly President and CEO of EAG Laboratories, a global scientific testing company headquartered in San Diego, California. He has also been a Director of USA-listed companies Newport Corporation (NSDQ: NEWP), Volcano Corporation (NSDQ: VOLC), Nuvasive, Inc (appointed February 2022) and was CEO and a Director of PhenomeX (NSDQ: CELL). He is currently a Non- Executive Director of ATS (Applied Technical Services). Prior to EAG, Siddhartha served as President of the Life Sciences Division at Life Technologies Corporation (NSDQ: LIFE), a publicly traded life sciences tools company. Siddhartha was also a management consultant at McKinsey & Company where his work focused on life sciences and healthcare related engagements. Siddhartha has lived and worked in the US, Japan, China, and India and has more than 20 years of international experience as a company director, executive and technical leader in the Life Sciences and TIC (testing, inspection and certification) sectors. He is a Chair of the Sustainability and Innovation Committee, a member of the People Committee.
    Ms Erica Mann Non-Executive Director Mar 2024
    Ms Mann is an experienced C-suite executive with a 30-year career across complex, regulated, multi-channel and multi product environment in top DAX, NYSE, NSDAQ pharmaceutical, OTC and FMCG multinationals. Before retiring as an executive, Erica led Bayer's Consumer Health Division, one of the OTC companies. Prior to joining Bayer, she was President and General Manager of Pfizer Nutrition following its acquisition of Wyeth Inc, where she served as Senior Vice President of Global Nutrition. This followed other senior executive roles of other Fortune 500 companies including Eli-Lily and Johnson & Johnson. She has held leadership positions in South Africa, Australia, New Zealand, Germany, Switzerland and the US. In addition to her executive experience in the nutrition and health industry, Erica has experience with global and emerging markets across Africa, China, Russia, and Brazil. Erica currently serves as an independent director of Perrigo, DSM-Firmenich and Kellogg (recently reincorporated as Kellanova) where she is a member of the Talent, Audit, and Social Responsibility & Public Policy Committees. Erica previously chaired the Board of the World Self-Medication Industry Association and served as an independent director with Blackmores Ltd and Solo-Flordis International.
    Mr Peter Possemiers Non-Executive Director Nov 2022
    Mr Possemiers has a background as a TIC sector expert with almost 40 years' experience working as a senior executive in leadership roles globally for SGS. He has lead teams both regionally and globally most notably SGS's global Environment Health and Safety business, a CHF 550 million business with a global headcount which exceeded 6,000. As Executive Vice President, he was a member of the SGS Operations Council with responsibility for the strategic growth and profitability of the business, leading 15 strategic acquisitions. He quickly moved into management roles in Singapore, Philippines, China and Korea, where he established and developed new markets including food, pharma, and mobile technology. In 2007, he was promoted to a role in Europe to manage the downstream OG&C business becoming the global market leader in this sector for SGS. In 2013, Peter was promoted to Executive Vice President,Global Environment, Health & Safety, a position based in Switzerland which he held for 8 years before moving into his most recent role as Vice President, Strategic Integration in 2021 following the acquisition of the Synlab A&S business, which covered the environmental, food, pharma and oil condition monitoring testing sector across Europe. He is a member of the Sustainability and Innovation Committee, and the Risk Committee.
    Mr Malcom Deane Chief Strategy Officer General Manager Life Sciences - Food & Pharma Americas GeneralChief Executive OfficerManaging Director Mar 2023
    Mr Deane has served the company in executive positions for the past 10 years in such roles as General Manager for Life Sciences Latin America, Food & Pharma Americas, and most recently as the Chief Strategy Officer, leading corporate strategy, business development and acquisitions.
    Mr Michael Paul Pearson Company Secretary Dec 2017
    -
    Ms Dayna Field Company SecretaryGeneral Counsel Oct 2024
    -
    Stuart Hutton Chief Financial Officer
    -
    Michael Paul Pearson Company Secretary
    -
    Dayna Field Company SecretaryGeneral Counsel
    -
    Tim Kilmister Executive General Manager Environmental
    -
    Andreas Jonsson Executive General Manager Food and Pharmaceutical
    -
    Bruce McDonald Executive General Manager Minerals
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited i 136,403,040 28.18%
    Citicorp Nominees Pty Limited 70,921,055 14.65%
    J P Morgan Nominees Australia Pty Limited 70,607,766 14.59%
    BNP Paribas Noms Pty Ltd. 24,099,533 4.98%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 12,963,781 2.68%
    BNP Paribas Nominees Pty Ltd. <Agency Lending A/C> 10,906,425 2.25%
    National Nominees Limited 9,081,446 1.88%
    Faircase Pty Ltd. 8,049,878 1.66%
    Australian Foundation Investment Company Limited 7,012,164 1.45%
    Washington H Soul Pattinson and Company Limited 6,737,845 1.39%
    Argo Investments Limited 5,104,023 1.05%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 3,235,312 0.67%
    Merrill Lynch (Australia) Nominees Pty Limited 2,428,867 0.50%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd.> 2,336,802 0.48%
    Netwealth Investments Limited <Wrap Services A/C> 2,226,863 0.46%
    HSBC Custody Nominees (Australia) Limited Gsi Eda 1,928,658 0.40%
    Ubs Nominees Pty Ltd. 1,583,443 0.33%
    Ms Maryon Catherine Campbell <The Checkmate A/C> 1,309,122 0.27%
    Mirrabooka Investments Limited 1,209,500 0.25%
    HSBC Custody Nominees (Australia) Limited ii 1,019,373 0.21%

    Profile

    since

    Note